Indeed, NLRP3 is activated in patients with inflammatory bowel disease and overexpression and constitutive activation of NLRP3 inflammasome contribute to the progression of head and neck squamous cell carcinoma (19, 20), lung cancer, and colorectal cancer (21, 22). This evidence concerns the gene NLRP3 and lung carcinoma.